Claims for Patent: 10,125,189

Summary for Patent: 10,125,189

Title:	Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
Abstract:	The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
Inventor(s):	Teschner; Wolfgang (Vienna, AT), Butterweck; Harald Arno (Vienna, AT), Pljevljakovic; Azra (Vienna, AT), Bauer; Theresa Friederike (Vienna, AT), Koelbl; Bernhard (Achau, AT), Schwarz; Hans-Peter (Vienna, AT), Nikolic; Nebojsa (Vienna, AT), Poelsler; Gerhard (Vienna, AT), Kindermann; Johanna (Maria Enzersdorf, AT)
Assignee:	Baxalta Incorporated (Bannockburn, IL) Baxalta GmbH (Zug, CH)
Application Number:	14/855,686
Patent Claims:	1. A method for preparing a concentrated immunoglobulin G (IgG) composition, comprising: (A) concentrating IgG in a solution to a first concentration of from 2% to 10% (w/v) by ultrafiltration using a first ultra-/diafiltration system comprising a first ultrafiltration membrane having a first nominal molecular weight cut off and a first surface area; (B) diafiltering the IgG in the solution against a diafiltration buffer using the first ultra-/diafiltration system comprising the first ultrafiltration membrane; and (C) concentrating the IgG in the solution to a second concentration of greater than 20% (w/v) by ultrafiltration using a second ultra-/diafiltration system comprising a second ultrafiltration membrane having a second nominal molecular weight cut off and a second surface area, wherein the second surface area of the second ultrafiltration membrane is less than the first surface area of the first ultrafiltration membrane. 2. The method of claim 1, wherein the surface area of the second ultrafiltration membrane is no more than a tenth of the surface area of the first ultrafiltration membrane. 3. The method of claim 1, wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are separately 100 kDa or less. 4. The method of claim 2, wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are separately 100 kDa or less. 5. The method of claim 1, wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are separately 50 kDa or less. 6. The method of claim 2, wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are separately 50 kDa or less. 7. The method of claim 1, wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are both 50 kDa. 8. The method of claim 2, wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are both 50 kDa. 9. The method of claim 1, wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are both 30 kDa. 10. The method of claim 2, wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are both 30 kDa. 11. The method of claim 1, wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2.+-.0.1. 12. The method of claim 2, wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2.+-.0.1. 13. The method of claim 8, wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2.+-.0.1. 14. The method of claim 10, wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2.+-.0.1. 15. The method of claim 1, further comprising, after concentrating the IgG in the solution using the first ultra-/diafiltration system: (D) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby recovering IgG lost from the solution; and (E) concentrating the recovered IgG using the second ultra-/diafiltration system comprising the second ultrafiltration membrane. 16. The method of claim 2, further comprising, after concentrating the IgG in the solution using the first ultra-/diafiltration system: (D) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby recovering IgG lost from the solution; and (E) concentrating the recovered IgG using the second ultra-/diafiltration system comprising the second ultrafiltration membrane. 17. The method of claim 8, further comprising, after concentrating the IgG in the solution using the first ultra-/diafiltration system: (D) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby recovering IgG lost from the solution; and (E) concentrating the recovered IgG using the second ultra-/diafiltration system comprising the second ultrafiltration membrane. 18. The method of claim 10, further comprising, after concentrating the IgG in the solution using the first ultra-/diafiltration system: (D) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby recovering IgG lost from the solution; and (E) concentrating the recovered IgG using the second ultra-/diafiltration system comprising the second ultrafiltration membrane.

Details for Patent 10,125,189

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	GAMMAGARD LIQUID	immune globulin infusion (human)	Injection	125105	April 27, 2005	10,125,189	2035-09-16
Octapharma Pharmazeutika Produktionsges.m.b.h.	CUTAQUIG	immune globulin subcutaneous (human)-hipp	Solution	125668	December 12, 2018	10,125,189	2035-09-16

International Patent Family for US Patent 10,125,189

Country	Patent Number	Estimated Expiration
Argentina	076607
Australia	2010253830
Australia	2016203542